Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies

Kinase Inhibitor ◽

Current Status ◽

B Cell Malignancies ◽

Inhibitor Development

Abstract 4634: Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies

10.1158/1538-7445.am2014-4634 ◽

2014 ◽

Author(s):

Eleonora Marostica ◽

Juthamas Sukbuntherng ◽

David Loury ◽

Jan D. Jong ◽

Xavier Woot de Trixhie ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Kinase Inhibitor ◽

Population Pharmacokinetic ◽

B Cell Malignancies ◽

Bruton's Tyrosine Kinase

Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies

Leukemia & Lymphoma ◽

10.1080/10428194.2021.1913139 ◽

2021 ◽

pp. 1-8

Author(s):

Wojciech Jurczak ◽

Simon Rule ◽

William Townsend ◽

David Tucker ◽

Barbara Sarholz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Human Trial

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

HemaSphere ◽

10.1097/01.hs9.0000562876.57990.65 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 520 ◽

Cited By ~ 3

Author(s):

J.N. Allan ◽

K. Patel ◽

A.R. Mato ◽

W.G. Wierda ◽

J. Pinilla-Ibarz ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Dose Escalation ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Preliminary Results ◽

Phase 1B

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Annals of the New York Academy of Sciences ◽

10.1111/nyas.12878 ◽

2015 ◽

Vol 1358 (1) ◽

pp. 82-94 ◽

Cited By ~ 21

Author(s):

Urte Gayko ◽

Mann Fung ◽

Fong Clow ◽

Steven Sun ◽

Elizabeth Faust ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Bruton's Tyrosine Kinase

Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

Annals of Oncology ◽

10.1093/annonc/mdy286.010 ◽

2018 ◽

Vol 29 ◽

pp. viii362-viii363 ◽

Cited By ~ 1

Author(s):

W. Jurczak ◽

S. Rule ◽

W. Townsend ◽

D. Tucker ◽

B. Sarholz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Human Trial

Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Haematologica ◽

10.3324/haematol.2021.280061 ◽

2021 ◽

Author(s):

John N. Allan ◽

Javier Pinilla-Ibarz ◽

Douglas E. Gladstone ◽

Krish Patel ◽

Jeff P. Sharman ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Dose Escalation ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Dose Escalation Study ◽

Phase 1B

Not available.

Abstract 4543: High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas.

10.1158/1538-7445.am2013-4543 ◽

2013 ◽

Author(s):

Lesley A. Mathews ◽

Rajarshi Guha ◽

Paul Shinn ◽

Ryan M. Young ◽

Kian-Huat Lim ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

High Throughput ◽

Kinase Inhibitor ◽

B Cell Lymphomas ◽

Novel Drug ◽

Large B Cell

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Signal Transduction and Targeted Therapy ◽

10.1038/s41392-020-00309-1 ◽

2020 ◽

Vol 5 (1) ◽

Author(s):

Juan Liu ◽

Qianmao Liang ◽

Aoli Wang ◽

Fengming Zou ◽

Ziping Qi ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Hodgkin Lymphoma ◽

Kinase Inhibitor ◽

Non Hodgkin Lymphoma

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Arthritis Research & Therapy ◽

10.1186/s13075-016-0988-z ◽

2016 ◽

Vol 18 (1) ◽

Cited By ~ 30

Author(s):

Jin Kyun Park ◽

Joo-Yun Byun ◽

Ji Ah Park ◽

Yu-Yon Kim ◽

Ye Ji Lee ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Mouse Model ◽

Tyrosine Kinase ◽

B Cell ◽

Kinase Inhibitor ◽

Potential Drug ◽

Monocyte Activation ◽

Bruton's Tyrosine Kinase

Faculty Opinions recommendation of Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718490094.793497269 ◽

2014 ◽

Author(s):

Stephan Stilgenbauer

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Kinase Inhibitor ◽

Cell Receptor ◽

Anticancer Therapy ◽

B Cell Receptor ◽

B Cell Malignancies ◽

B Cell Receptor Signaling ◽

Cell Receptor Signaling